Jiangsu Hengrui Pharmaceuticals (SHA:600276) subsidiaries obtained the approval of China's drug administrator to start clinical trials for a novel combination therapy for non-small cell lung cancer, according to a Thursday filing with the Shanghai bourse.
The trial will test SHR-A2102, the company's proprietary Nectin-4 targeting antibody-drug conjugate, alongside other agents. SHR-A2102 will be combined with adebrelimab, with or without the anti-CTLA-4 antibody SHR-8068, as well as paired with aumolertinib mesylate.
Shares of the pharmaceutical company rose 1% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments